COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?

OBJECTIVES: The patients with hematological malignancies are a vulnerable group to COVID-19, due to the immunodeficiency resulting from the underlying disease and oncological treatment that significantly impair cellular and humoral immunity. Here we report on a beneficial impact of a passive immunot...

Descripción completa

Detalles Bibliográficos
Autores principales: Rnjak, D., Ravlić, S., Šola, A.-M., Halassy, B., Šemnički, J., Šuperba, M., Hećimović, A., Kurolt, I.-C., Kurtović, T., Mačak Šafranko, Ž., Polančec, D., Bendelja, K., Mušlin, T., Jukić, I., Vuk, T., Zenić, L., Artuković, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064810/
https://www.ncbi.nlm.nih.gov/pubmed/33901641
http://dx.doi.org/10.1016/j.tracli.2021.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064810/
https://www.ncbi.nlm.nih.gov/pubmed/33901641
http://dx.doi.org/10.1016/j.tracli.2021.04.004

Ejemplares similares